EUVIMEDEUVIMED entdecken
Crossref

Decreasing parvovirus B19 and hepatitis A nucleic acid test positivity rates in Canadian plasma donors following the initiation of COVID ‐19 restriction in March 2020

Steven J Drews iD, Carmen Charlton iD, Sheila F O'Brien iD, Samantha Burugu, Gregory A Denomme iD

Vox Sanguinis · 2024

DOI: 10.1111/vox.13616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Steven J Drews und 4 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology, Canadian Blood Services, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: COVID-19, Blood Donors, Parvovirus B19, Human. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives In Canada, plasma sent for fractionation is tested for both parvovirus B19 (B19V) and hepatitis A virus (HAV). This study compared positivity rates of B19 and HAV nucleic acid tests (NATs) in Canadian plasma samples for the pre‐COVID‐19 restriction era (2015 to end of February 2020 [Q1] 2020) and the post‐COVID‐19 restriction era. Materials and Methods Pooled EDTA plasma specimens were tested within 24 months of blood draw using the Procleix Panther System (Grifols Diagnostic Solutions Inc, San Diego, CA, USA) for B19V and HAV detection. Reactive pools were resolved by individual specimen testing.

Results

Between 1 January 2015, and 31 March 2022, 3,928,619 specimens from Canadian plasma donors were tested for B19V. For the same period, 3,922,954 specimens were tested for HAV. To account for a lag in specimen testing for up to 24 months, the data were divided into: (1) a pre‐pandemic period (1 January 2015–31 March 2020; B19V tested n = 2,412,701, B19V NAT‐positive n = 240 [0.01%], HAV tested n = 2,407,036, HAV NAT‐positive n = 26 [0.001%]); (2) a two‐year mixed‐impact period (1 April 2020–31 March 2022; B19V tested n = 968,250, B19V NAT‐positive n = 14 [0.001%], HAV tested n = 968,250, HAV NAT‐positive n = 2 [0.0002%]); and (3) a pandemic‐impact period (1 April 2022–31 March, 2023; B19V tested n = 597,668, B19V NAT‐positive n = 3 [0.0005%], HAV tested n = 597,668, HAV NAT‐positive n = 1 [0.0002%]).

Conclusion

The percentage of B19V‐ and HAV‐positive donations was significantly reduced from the pre‐pandemic period to the pandemic‐impact period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Blood DonorsParvovirus B19, HumanHumansCanadaHepatitis ASARS-CoV-2MaleFemaleHepatitis A virusParvoviridae Infections

Stichwörter der Autor:innen

COVID‐19hepatitis A virusnucleic acid testpandemic restrictionsparvovirus B19

Autor:innen und Institutionen

  • Microbiology, Canadian Blood Services, Edmonton, Alberta, Canada.
  • Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
  • Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario, Canada.
  • School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
  • Grifols Canada Ltd, Mississauga, Ontario, Canada.
  • Grifols Laboratory Solutions, San Marcos, Texas, USA.

ORCID-Profile: Steven J Drews, Carmen Charlton, Sheila F O'Brien, Gregory A Denomme

Zitieren

APA

Drews, S. J., Charlton, C., O'Brien, S. F., Burugu, S., & Denomme, G. A. (2024). Decreasing parvovirus B19 and hepatitis A nucleic acid test positivity rates in Canadian plasma donors following the initiation of COVID ‐19 restriction in March 2020. Vox Sanguinis. https://doi.org/10.1111/vox.13616

Vancouver

Drews SJ, Charlton C, O'Brien SF, Burugu S, Denomme GA. Decreasing parvovirus B19 and hepatitis A nucleic acid test positivity rates in Canadian plasma donors following the initiation of COVID ‐19 restriction in March 2020. Vox Sanguinis. 2024. doi:10.1111/vox.13616

BibTeX
@article{Drews2024,
  author = {Drews, Steven J and Charlton, Carmen and O'Brien, Sheila F and Burugu, Samantha and Denomme, Gregory A},
  title = {Decreasing parvovirus B19 and hepatitis A nucleic acid test positivity rates in Canadian plasma donors following the initiation of COVID ‐19 restriction in March 2020},
  journal = {Vox Sanguinis},
  year = {2024},
  doi = {10.1111/vox.13616}
}
Kostenlos starten →